Mafenide

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Mafenide" – news · newspapers · books · scholar · JSTOR (September 2022) (Learn how and when to remove this message)

Mafenide

Clinical data
Trade names	Sulfamylon, Mafylon
AHFS/Drugs.com	Monograph
Routes of administration	Topical
ATC code	D06BA03 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name 4-(Aminomethyl)benzenesulfonamide
JSmol)	Interactive image
SMILES O=S(=O)(c1ccc(cc1)CN)N
InChI InChI=1S/C7H10N2O2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11) Y Key:TYMRLRRVMHJFTF-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Mafenide (

Mafenide works by reducing the bacterial population present in the avascular tissues of burns and permits spontaneous healing of deep partial-thickness burns. ^[citation needed]

Adverse reactions

Adverse reactions can include superinfection, pain or burning upon application, rash, pruritus, tachypnea, or hyperventilation. Mafenide is metabolized to a carbonic anhydrase inhibitor, which could potentially result in metabolic acidosis.^[4]

Drug interactions

There are no significant interactions.^{[citation needed]}

Contraindications

Mafenide is contraindicated in those with sulfonamide hypersensitivity or renal impairment.

Dosage

For use as adjunctive therapy for second- and third-degree burns to prevent infection, adults and children should apply topically to a thickness of approximately 1.6 mm to cleaned and debrided wound once or twice per day with a sterile gloved hand. The burned area should be covered with cream at all times.^{[citation needed]}

References